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Abstract Implantable cardioverter-defibrillators (ICDs)
significantly reduce mortality in patients with depressed left
ventricular ejection fraction (LVEF) and heart failure (HF).
However, shortcomings of LVEF to accurately identify
those at greatest risk of ventricular tachyarrhythmias have
led to the pursuit of alternative means to refine qualification
criteria for ICD implantation. It is well established that
imaging the cardiac nervous system with123I meta-
iodobenzylguanidine (123I-mIBG) provides incremental
prognostic value in patients with HF beyond LVEF.
Whether 123I-mIBG will also play an important role for
identifying and/or predicting sustained ventricular tachyar-
rhythmias in patients with cardiomyopathy and determining
those who may benefit from ICD implantation is currently
under investigation. Novel imaging approaches that pin-
point the site of ventricular arrhythmias and guide ventric-
ular tachycardia ablation are presented.
Keywords CardiacmIBG . Cardiomyopathy . Ventricular
tachycardia . Cardiac arrhythmia . Heart failure . Ablation
therapy . Cardiomyopathy
Introduction
Sudden cardiac death is a significant public health issue,
affecting 150,000-450,000 patients in the United States each
year [1, 2]. Clinical trial data has shown that implantable
cardioverter-defibrillators (ICDs) significantly reduce mor-
tality in patients with depressed left ventricular ejection
fraction (LVEF) and heart failure (HF), whereas antiarrhyth-
mic medication has not been shown to have the same ben-
efits compared to placebo [3, 4]. Identifying patients at risk
for developing ventricular tachyarrhythmias who will bene-
fit from ICD placement for primary prevention has been the
objective of a multitude of large clinical trials over the past
two decades. The focus has been on patients with structural
heart disease, and the most valuable discriminator currently
in use is LVEF. However, the majority of patients who suffer
SCD do not have characteristics that would qualify them for
an ICD for primary prevention [5, 6]. Furthermore, in a large
randomized primary prevention ICD implantation trial, over
two thirds of patients who received ICDs with depressed
LVEF never received ICD therapy during a follow-up period
of almost 2 years [7]. These shortcomings of LVEF to
accurately identify those at greatest risk of ventricular ar-
rhythmias (VTA) have led to the pursuit of alternative
means to refine implantation qualification criteria for ICDs.
Signal-averaged electrocardiogram (ECG), microvolt T-
wave alternans, electrophysiologic testing, serum markers
(including brain natriuretic peptide), and autonomic func-
tion evaluation (including heart rate variability (HRV), baro-
reflex sensitivity, heart rate turbulence, and deceleration
capacity of heart rate) have all been studied, and have
produced variable results [8]. More recently, imaging the
cardiac nervous system has proven to have incremental
prognostic value in patients with HF beyond LVEF and B-
type natriuretic peptide (BNP).This article will summarize
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the data on imaging cardiac innervations with 123I meta-
iodobenzylguanidine (123I-mIBG) SPECT and its potential
role in predicting the risk of VTA and describe novel imag-
ing approaches to identify the site of VTA to guide ventric-
ular tachycardia (VT) ablation.
Imaging the Cardiac Sympathetic Nervous System
123I-mIBG has been the most common radiotracer studied
for imaging cardiac innervation. It was first introduced in
1979 for imaging the adrenal medulla, and for the heart
shortly thereafter [9]. 123I-mIBG is chemically modified
from guanethidine, which is an analogue of the endogenous
neurotransmitter norepinephrine, and uses the same uptake
and storage mechanisms as norepinephrine. Two mecha-
nisms of 123I-mIBG uptake from the synaptic cleft have
been identified, one being neuronal and the other being
non-neuronal, of which the former predominates in the
human heart. This is evidenced by the fact that uptake is
absent in enervated transplanted hearts [10]. Unlike norepi-
nephrine, 123I-mIBG is not metabolized by monoamine ox-
idase or catechol-O-methyltransferase, and does not interact
with postsynaptic receptors. Thus, cardiac 123I-mIBG re-
flects uptake in only presynaptic sympathetic fibers in the
myocardium [11].
123I-mIBG cardiac images are usually acquired in the
anterior planar view 5–40 minutes (early) and again 3–
4 hours (delayed) after the injection of the radiotracer.
From these planar images, the heart-to-mediastinal ratio
(H/M) is calculated by dividing the mean counts per pixel
from a cardiac region of interest by the mean counts per
pixel from an area in the upper mediastinum. Delayed H/M
ratio derived from the anterior planar view has been widely
used to predict patient outcome and monitor response to
medical treatment. In addition, 123I-mIBG washout rate
(WR) is calculated by comparing early and delayed 123I-
mIBG activities in the heart, reflecting the retention or
turnover of 123I-mIBG in neurons. After each planar acqui-
sition, a SPECT acquisition is performed, and images are
analyzed in conventional orthogonal planes (short axis, ver-
tical long axis, and horizontal long axis).
The reproducibility and inter-observer variability of 123I-
mIBG in HF patients at single centers has been found to be
acceptable and highly reproducible [12]. However, inter-
institutional variations exist which have been attributed to
the use of different collimators, image acquisition parameters,
injected doses, region of interest settings, 123I-mIBG labeling
methods, disease status, and 123I-mIBG isotopes[13]. Also,
some patterns across patient populations have been noted. For
example, in healthy subjects, inferior wall uptake of 123I-
mIBG may decrease with age, especially in men [14]. Given
the inter-institutional variations, a standardized protocol was
recently proposed by the Cardiovascular Committee and the
European Council of Nuclear Cardiology [11].
The Clinical Utility of123I-mIBG in HF
The autonomic nervous system is known to play a key role
in the pathophysiology of HF. Neurohormonal feedback
provides a means for compensation in the early stages of
HF; however, as the disease progresses, chronic sympathetic
output leads to detrimental effects, including interstitial
fibrosis and left ventricular remodeling. Chronically elevat-
ed norepinephrine levels have been linked to an increased
risk of mortality in HF [15]. Additionally, pharmacologic
blockade of the sympathetic input to the heart decreases
mortality in these patients [16, 17].
Multiple clinical trials have evaluated 123I-mIBGin HF
patients. Patients with HF exhibit decreased cardiac uptake
of 123I-mIBG (decreased H/M), and earlier release of 123I-
mIBG from early to delayed imaging due to compromised
neuronal integrity (increased WR). An inverse relationship
has been shown between severity of HF classification and
H/M 123I-mIBG ratio. Retrospective and single center stud-
ies over the past two decades have demonstrated that 123I-
mIBGuptake predicts the risk of cardiac death cardiomyop-
athy (Table 1) [18–25]. Preliminary data also suggest salu-
tary effects of medical therapy on cardiac 123I-mIBG uptake
and its relation to clinical outcomes [19, 26]. Several small
series have demonstrated improvement in sympathetic in-
nervation, as assessed with 123I-mIBGscintigraphy, resulting
from cardiac resynchronization therapy and left ventricular
assist device therapy, which paralleled multiple clinical pa-
rameters [27–29]. Conversely, non-responders to CRT did
not demonstrate the same improvements in sympathetic
innervation [30, 31].
A meta-analysis of 18 small trials including 1755 patients
was published in 2008, and demonstrated that decreased
H/M and elevated WR portends a worse prognosis, with
increased risk of cardiac death and cardiac events [32].
Based on the aforementioned data and similar results in
previously published trials, 123I-mIBG has gained clinical
use in Europe and Japan in HF patients and for cardiac
transplantation candidacy since the 1990s. In the U.S., how-
ever, 123I-mIBG has not yet received Food and Drug
Administration (FDA) approval for cardiac application [33].
AdreView Myocardial Imaging for Risk Evaluation in
Heart Failure (ADMIRE-HF) prospective, multinational,
multicenter, open-label study which enrolled 961 patients
with LVEF≤35 % and New York Heart Association
(NYHA) functional class II-III was recently completed
[34••]. Patients underwent both 123I-mIBGand myocardial
perfusion imaging and were followed for two years. The
subgroup of patients with 123I-mIBGH/M<1.6 had a 2-year
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cardiac event rate (progression of NYHA class, potentially
life threatening arrhythmias, or cardiac death) of 37 %,
while those with H/M≥1.6 had a 2-year event rate of
15 %. Each of the three components of the primary outcome
were also significantly reduced in patients with H/M≥1.6
(composite primary outcome: HR=0.4, p<0.001; HF pro-
gression: HR=0.49, p=0.002; life-threatening arrhythmia:
HR=0.37, p=0.02; cardiac death: HR=0.14, p=0.006).
LVEF, BNP, NYHA class, and H/M were significantly pre-
dictive of event occurrence in multivariate analysis. Although
WR was predictive in univariate analysis, it did not remain so
in multivariate analysis.
123I-mIBG for Assessment of Ventricular Arrhythmia
Risk
Activation of sympathetic nervous system is an important
factor in the pathophysiology of ventricular tachyarrhythmias.
All three known mechanisms of ventricular tachyarrhythmias,
Table 1 Relevant Studies studies on mIBG Scintigraphy scintigraphy for Prognosis prognosis in HF









1992 Merlet, et al. [18] 90 27 22 II-IV 11 H/M was more valuable in predicting survival
than x-ray cardiothoracic ratio, echocardio-
graphic end-diastolic diameter and
radionuclide LVEF
1998 Nakata, et al. [35] 414 32 49 1.6 (mean) 22 Late H/M, early H/M, use of nitrates, and LVEF
were all predictive of cardiac death, but late
H/M was the most powerful predictor
1999 Cohen-Solal,
et al. [20]
93 26 25 2.6 (mean) 10 In patients with chronic HF, late H/M and peak
oxygen consumption were predictive of death
or heart transplantation, but only peak VO2
was significant by multivariate analysis
1999 Merlet, et al. [24] 112 0 21 II-IV 27 Of several variables tested, only late H/M and




171 56 27 1.9 (mean) 27 Elevated WR was an independent predictor of
cardiac death; elevated WR and BNP predicted
progressive HF
2001 Ogita, et al. [25] 79 57 29 1.8 (mean) 31 WR≥27 % predicted SCD, HF death, and
worsening HF
2002 Gerson, et al. [26] 22 0 25 II-IV 7.2 Patients with abnormal baseline 123I-mIBG uptake
demonstrated improvement in 123I-mIBG uptake
with carvedilol treatment, which correlated with
improvement in LVEF.
2003 Kasama, et al. [36] 30 0 33 2.8 (mean) 6 Spironolactone decreased total defect score, and
WR and increased H/M in HF patients to placebo.
These changes correlated with improvement in
LVEF, LV end-diastolic volume, and NYHA class.
2003 Yamada, et al. [21] 65 63 28 2.1 (mean) 34 In multivariate analysis, only WR (not H/M or HRV)
was predictive of cardiac events
2005 Nakata, et al. [19] 88 27 27 2.6 (mean) 43 Less severe 123I-mIBG defect correlated with
improved treatment effect from beta-blockers
and/or ACE inhibitors (Mortality reduction from
36 % to 12 % in those with H/M≥1.53, from
53 % to 37 % in those with H/M<1.53)
2008 Agostini, et al. [22] 290 42 32 2.5 (mean) 24 In this retrospective analysis, decreased H/M LVEF
were both predictive of major cardiac events
2008 Kasama, et al. 208 42 32 2.6 (mean) 53 Patients underwent serial 123I-mIBG imaging, and Δ
WR was shown to be an incremental predictor of
cardiac death and sudden death
2010 Jacobson,
et al. [34••]
961 66 27 2.16 (mean) 17 Late H/M, in addition to LVEF, BNP, and NYHA
class was an independent predictor of HF
progression, arrhythmic events, and cardiac death.
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including enhanced automaticity, triggered automaticity, and
reentrance, can be potentiated by the sympathetic nervous
system. Sympathetic neuronal innervation has been shown
to be denser in those with ventricular arrhythmias than in
those without [37]. It is theorized that denervated but viable
myocardium may demonstrate an exaggerated response to
circulating catecholamines [38].
It was observed over two decades ago that abnormal 123I-
mIBGuptake was present after myocardial infarction (MI)
and correlated with ventricular ectopy [39] and with induc-
ible ventricular tachyarrhythmias during invasive electro-
physiologic testing [40], as well as in patients without
coronary artery disease but with spontaneous ventricular
tachyarrhythmias [41]. These small series sparked a long
pursuit to uncover the predictive value of 123I-mIBGfor
ventricular tachyarrhythmias, to refine the utilization of
ICDs, and to determine a possible clinical role for cardiac
123I-mIBGtesting. Multiple studies have evaluated the value
of 123I-mIBGimaging in diverse groups of patients to predict
the risk of ventricular tachyarrhythmias, sudden cardiac
death, and ICD discharges (Table 2) [42–51].
HF Patients. Prospective observational studies have shown
that123I-mIBG may predict the risk of ICD discharges in
patients with mild-to-moderate HF. In 97 patients with
LVEF<40 % and an average NYHA functional class II
who underwent cardiac 123I-mIBG imaging, both WR and
early and late H/M were predictive of sudden cardiac death
[52]. Over a mean follow-up of 65 months, the prevalence
of sudden cardiac death was significantly higher in patients
with 123I-mIBG WR≥27 % compared to those with WR<
27 %; 25%and 4 %, respectively. In another series of pa-
tients with NYHA class I-II HF and recent ICD implanta-
tion, 123I-mIBG WR, in addition to baroreflex sensitivity
and heart rate variability, was found to correlate directly
with the incidence of ICD firings [53].
The largest prospective, multicenter study to date designed
to examine the predictive value of 123I-mIBGscintigraphy for
predicting ICD implantation and discharge in HF patients was
published in 2010. Among 116 patients (mean LVEF=28 %,
96 % ischemic etiology, mean NYHA class=2.9) who
underwent 123I-mIBGcardiac imaging prior to ICD implanta-
tion, 52 % of patients with large 123I-mIBG defects (summed
score>26) received appropriate ICD therapy (primary end-
point) during a mean follow up period of 23 months versus
only 5% of patients with a smaller 123I-mIBG defect (p<0.01).
Moreover, 57 % of those with a large 123I-mIBG defect expe-
rienced the secondary endpoint of appropriate ICD discharge
or cardiac death versus only 10% of those with smaller defects
(p<0.01) [54••].
Non-HF Patients. Populations known to be at risk for ven-
tricular tachyarrhythmias but without a history of HF have
also been evaluated for cardiac 123I-mIBG abnormalities. In
patients with Brugada syndrome, 47 % were found to have
regional 123I-mIBG defects, most commonly in the inferior
and septal regions [55]. Among patients with long QT
syndrome, 61 % were found to have regional 123I-mIBG
defects, most commonly in the anteroseptal region. No
difference in 123I-mIBG uptake pattern was noted between
different long QT syndrome subtypes, between those with
corrected QT (QTc)>500 ms vs. those with QTc<500 ms, or
between those suffering from cardiac arrest or syncope [56].
Other groups for which 123I-mIBG imaging abnormalities
may predict the risk for ventricular tachyarrhythmias are
those with idiopathic ventricular fibrillation [43, 44],
arrhythmogenic right ventricular dysplasia [46],hypertro-
phic cardiomyopathy [47],Chagas cardiomyopathy [49],
and after surgical correction of tetralogy of Fallot [57].
Integration of 3-Dimensional Scar Models
from 123I-mIBGNeuro-Cardiac Imaging to Guide
Ventricular Tachycardia Ablation
The localized information of abnormal 123I-mIBG uptake
pattern in the heart has raised the possibility that regional
inhomogeneities of innervation may be related to ventricular
arrhythmias and could provide guidance for VT ablations.
Magnetic resonance imaging (MR), positron emission to-
mography (PET) and computed tomography (CT) have all
been well validated to provide detailed information about
the cardiac anatomy or the myocardial scar, which is usually
the target for substrate-guided ventricular tachycardia abla-
tions [58•, 59, 60, 61]. The current “gold standard” of
defining myocardial scar is based on endocardial bipolar
voltage recordings. Using a 3D mapping system a roving
mapping catheter is moved sequentially along the endocar-
dial surface of the left ventricle. Assuming that the voltage
amplitude will be lower on scarred myocardium due to a
paucity of live cells, a tiered classification with >1.5 mV for
normal myocardium, 0.5-1.5 mV for abnormal myocardium
and <0.5 mV for scar is generally accepted for defining scar
and its border zone in the left ventricle [62]. These clinical
criteria were derived from several animal and patient studies
correlating bipolar endocardial voltage recordings to areas of
previous myocardial infarction.
Only recently has PET imaging been used to guide and
facilitate VT ablation [58•]. Investigators at the University
of Maryland showed a good correlation between PET-
derived metabolic scar maps and endocardial voltage maps
in patients undergoing VT ablation (r=0.89, p<0.05).
Additionally, 3D scar reconstructions were successfully reg-
istered in patients with a commercial mapping system with
an acceptable registration error of 3.7±0.7 mm. Scar size,
location, and border zone accurately predicted high-
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resolution voltage map findings (r=0.87; p<0.05). After
integration of metabolic maps relevant information was
available during the procedure. Low voltage recordings
within wall segment displaying preserved metabolic activity
were shown to be due to suboptimal catheter contact rather
than actual myocardial wall disease. Integrated scar maps
revealed metabolically active channels within the myocardial
scar, which were not detected by voltage mapping. Moreover,
PET/CT maps correctly predicted non-transmural epicardial
scar that was confirmed with epicardial mapping despite
Table 2 Relevant studies on mIBG scintigraphy and ventricular tachyarrhythmias







1991 McGhie, et al. [39] 27 Post-MI - - Higher total defect score on 123I-mIBG correlated
with the presence of VT and ventricular ectopy
within 10 days post-MI
2001 Daliento, et al. [57] 22 Post-surgical correction
of tetralogy of Fallot
- - Those with VTA on 24-hour Holter monitoring
had significantly reduced 123I-mIBG uptake and
increased WR than those without.
2003 Arora, et al. [42] 17 Prior ICD discharges 39 - 10 patients with a history of ICD discharges had
significantly lower H/M and higher WR, as well
as reduced values for several HRV parameters,
than 7 patients without prior ICD discharges
2003 Terai, et al. [47] 44 HCM 59 - Mean WR was significantly higher in 15 patients
with VTA on 24-hour Holter monitor than in
29 without.
2006 Paul et al. [43] 20 Idiopathic VTA with
structurally normal
hearts
72 86 18 recurrent episodes occurred in 4 patients with
abnormal 123I-mIBG uptake, whereas only 2
episodes occurred in 1 patient with normal
123I-mIBG uptake.
2007 Kioka, et al. [52] 97 CHF (53 % ICM, mean
NYHA class 2.1)
29 65 Early and late H/M and WR were all predictive
of SCD
2008 Bax, et al. [50] 50 CHF (62 % ICM) 32 - Patients underwent 123I-mIBG prior to EP testing.
4-hour 123I-mIBG TDS≥37 predicted EP positivity.
2009 Akutsu, et al. [44] 86 Prior VTA 59 132 H/M≤2.8 predicted recurrence of VTA (HR 3.6
[95 % confidence interval, 1.4-9.2, P=0.007]).
2009 Koutelou, et al. [53] 25 Compensated CHF (NYHA
class I-II) and recent
ICD implantation.
36 32 WR, in addition to HRV and baroreflex sensitivity,
predicted ICD discharges
2010 Boogers, et al.
[54••]
116 HF 28 23 123I-mIBG SPECT was performed before ICD
implantation. Those with late 123I-mIBG SPECT
defect score>26 had a greater risk of appropriate
ICD therapy (52 % vs. 5 %, p<0.01).
2010 Nishisato, et al. [45] 60 Diverse group of patients
undergoing ICD
implantation
49 29 At the time of ICD implant, 123I-mIBG planar and
technetium SPECT perfusion imaging were
performed. H/M≤1.9 with summed perfusion
score≥12 independently predicted elevated risk
of ICD discharge.
2011 Paul, et al. [46] 42 Arrhythmogenic right
ventricular
cardiomyopathy
- 143 Patients underwent 123I-mIBG SPECT, and 59 %
were found to have abnormal uptake. Abnormal
uptake predicted future VTA.
2011 Miranda, et al. [49] 26 Chagas cardiomyopathy
with and without VTA
53 - Compared to patients without of VTA on 24-hour
Holter monitoring, those with VTA had an
increased 123I-mIBG defect score.
2012 Kasama, et al. [51] 56 Dilated cardiomyopathy 31 54 Late potentials and 123I-mIBG imaging was
performed. Those with late potential positivity
and WR>50 % had an elevated risk of SCD.
2012 Marshall et al. [48] 27 HF patients receiving an
ICD for primary
prevention
24 16 Low H/M and high total 123I-mIBG SPECT defect
score at the time of ICD implantation predicts
future ICD discharges
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normal endocardial map. Similar results were obtained when
using SPECT rather than PET radiopharmaceuticals [59].
An alternate attractive approach is the combination of
PET with either CT or MR. While PET provides the meta-
bolic differentiation between normal, hibernating, and
scarred myocardium detailed anatomic information can be
obtained from CT or MR with a spatial resolution of ≤1 mm
or 2–3 mm, respectively. Fusing both datasets can enable a
synergistic metabolic and morphological evaluation, which
extends beyond what each imaging technique can offer as a
stand-alone technology. New elastic algorithms are able to
register PET with CT or MR images from separate scanners
fast and with an accuracy that is similar to manual elastic
registration performed by human experts using up to 32
anatomic landmarks [63].
Current ongoing studies evaluate the utility of regional
123I-mIBG abnormalities to guide ablation in patients with
preexisting cardiomyopathy and ventricular arrhythmias. 3D
reconstructions of the regional left ventricular 123I-mIBG
innervation have been compared to high density voltage
maps. Using the conventional 17-segment analysis [64],
the concordance between voltage-defined scar and 123I-
mIBG denervation defect was found to be 75 %. Among
the 25 % discordant segments, 20 % of the mismatch seg-
ments exhibited a larger123I-mIBG defect size when com-
pared to the voltage scar. While 90 % of subsequent
successful VT ablation sites were found in the area of
voltage-defined scar, 10 % were located in an area of ab-
normal 123I-mIBG uptake that exhibited preserved voltage
[65]. In a subset of patients who underwent repeat 123I-
mIBG imaging within 6 months of VT ablation, there was
a trend toward increased late H/M among patients with
recurrent VT and decreased late H/M in those without re-
current VT. While this difference did not reach statistical
significance, it was hypothesized that regeneration of sym-
pathetic nerves within areas of scar may predispose these
patients to VT, and may be reflected by increased 123I-mIBG
(Fig. 1) [66].
Assessment of Cardiac Innervation with PET
Radiotracers
Position emitting radiotracers have also been used to image
the cardiac sympathetic nervous system using PET [67, 68].
The most common PET radiotracer studied for this purpose
has been carbon-11 labeled hydroxyephedrine (11C-HED).
11C-HED is taken up by cardiac presynaptic neurons but not
metabolized by synaptic degradation enzymes. Similar to
the 123I-mIBG planar and SPECT data, decreased 11C-HED
PET retention in patients with HF has been associated with
increased cardiac mortality and need for cardiac transplan-
tation [69, 70]. PET imaging of the cardiac nervous system
is advantageous over single photon imaging due to its su-
perior spacial and temporal resolution compared to planar
and SPECT techniques. However, widespread clinical use of
11C-HED is limited due to its relatively short 20 minute half-
life and complex production requiring an onsite cyclotron,
which makes the entire production costly [68].
Reduced cardiac neural regeneration after myocardial
infarction has been theorized to be associated with arrhyth-
mia risk. This was tested in a swine model, in which perfu-
sion was assessed by 13N-ammonia and innervation by 11C-
epinephrine 4 to 12 weeks after myocardial infarction in-
duced by balloon occlusion of the left anterior descending
artery. Inducible VT was present in seven of the 11 animals
studied, and in those with inducible VT, a significantly
larger area of perfusion/innervation mismatch was present
[71]. These findings lead to the PARAPET study, a prospec-
tive, observational trial, which will assess if hibernating
myocardium or inhomogeneity of sympathetic innervation
measured with PET can predict sudden cardiac death or
cardiovascular mortality [72].
Conclusions
The clinical and prognostic value of imaging the cardiac
nervous system in HF with123I-mIBG is well established.
While the radiotracer has not yet received FDA approval
for cardiac application in the US, its potential role may
also expand to the arena of electrophysiology, identifying
and/or predicting sustained ventricular tachyarrhythmias in
patients with cardiomyopathy, determining those who may
benefit from ICD implantation, and pinpointing the site of
Fig. 1 Four-hour delayed MIBG images in panels A and B show
decreased uptake of MIBG after ablation in a patient with VT. Panels
C and D show increased uptake of MIBG after ablation in a different
patient with VT. (A and C: before ablation, B and D: after ablation)
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ventricular arrhythmias to guide ventricular tachycardia
ablation procedures.
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